Serina Therapeutics Inc (SER)

$1.81 -0.01 (-0.55%)
Market Cap 27.15M
Revenue (ttm) 130,000.00
Net Income (ttm) -19.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -14,753.85%
Debt to Equity Ratio 0.17
Volume 77,000
Avg Vol 104,556
Day's Range N/A - N/A
Shares Out 15.00M
Stochastic %K 21%
Beta 1.15
Analysts Strong Sell
Price Target $13.00

Company Profile

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has c...

Industry: Biotechnology
Sector: Healthcare
Phone: 256 327 9630
Address:
601 Genome Way, Suite 2001, Huntsville, United States
littleimagination
littleimagination Jun. 26 at 4:33 PM
$SER Dont you mean 12.5 million? and not 125 mil, I didnt see anything on google or anywhere else stating 125 mil.
0 · Reply
focafoca99
focafoca99 Jun. 24 at 8:23 PM
$SER increased its authorized common shares to 125 million after shareholder approval at its annual meeting.
0 · Reply
Street_secrets
Street_secrets Jun. 24 at 10:33 AM
$SER Small entry... upside on the table
0 · Reply
KaShing01
KaShing01 Jun. 19 at 7:57 PM
$SER I have a hunch Fed Kevin Warsh will surprise everyone and cut rates soon, regardless.
0 · Reply
dthekang
dthekang Jun. 19 at 12:42 AM
$SER something happening?
1 · Reply
Rampageusa
Rampageusa Jun. 18 at 5:51 PM
$SER 7% move….lets go..
0 · Reply
KaShing01
KaShing01 Jun. 17 at 5:18 PM
$SER Just increase my position.
0 · Reply
dthekang
dthekang Jun. 16 at 2:45 PM
$SER 🔥
1 · Reply
dthekang
dthekang Jun. 15 at 3:21 PM
$SER huh?
0 · Reply
robiein35
robiein35 Jun. 11 at 8:06 PM
$SER why the hike? Any news?
1 · Reply
Latest News on SER
Serina Therapeutics Transcript: AGM 2026

Jun 17, 2026, 12:00 PM EDT - 11 days ago

Serina Therapeutics Transcript: AGM 2026

Serina Therapeutics files to sell 16.45M shares of common stock for holders

2026-05-22T20:06:20.000Z - 5 weeks ago

Serina Therapeutics files to sell 16.45M shares of common stock for holders

Serina Therapeutics Registration statement: Registration filing

May 22, 2026, 8:00 AM EDT - 5 weeks ago

Serina Therapeutics Registration statement: Registration filing

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

May 14, 2026, 4:20 PM EDT - 6 weeks ago

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Serina Therapeutics Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 6 weeks ago

Serina Therapeutics Quarterly report: Q1 2026

Serina Therapeutics Earnings release: Q1 2026

May 14, 2026, 7:00 AM EDT - 6 weeks ago

Serina Therapeutics Earnings release: Q1 2026

Serina Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Serina Therapeutics Proxy statement: Proxy filing

Serina Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Serina Therapeutics Proxy statement: Proxy filing

Serina Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 2 months ago

Serina Therapeutics Proxy statement: Proxy filing

Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit

Apr 7, 2026, 6:00 AM EDT - 2 months ago

Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit

Serina Therapeutics announces NYSE acceptance of plan to regain compliance

2026-04-02T20:21:42.000Z - 3 months ago

Serina Therapeutics announces NYSE acceptance of plan to regain compliance

Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan

Apr 2, 2026, 4:13 PM EDT - 3 months ago

Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan

Serina Therapeutics Annual report: Q4 2025

Mar 25, 2026, 8:00 AM EDT - 3 months ago

Serina Therapeutics Annual report: Q4 2025

Serina Therapeutics Earnings release: Q4 2025

Mar 25, 2026, 8:00 AM EDT - 3 months ago

Serina Therapeutics Earnings release: Q4 2025

Serina Therapeutics Transcript: 38th Annual Roth Conference

Mar 24, 2026, 3:30 PM EDT - 3 months ago

Serina Therapeutics Transcript: 38th Annual Roth Conference

Serina Therapeutics to Present at the 38th Annual Roth Conference

Mar 24, 2026, 6:00 AM EDT - 3 months ago

Serina Therapeutics to Present at the 38th Annual Roth Conference

Serina Therapeutics names Greg Bailey co-chairman

2026-03-18T20:30:41.000Z - 3 months ago

Serina Therapeutics names Greg Bailey co-chairman

Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease

Mar 18, 2026, 4:10 PM EDT - 3 months ago

Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease

Serina Therapeutics Slides: Investor presentation

Mar 16, 2026, 8:00 AM EDT - 3 months ago

Serina Therapeutics Slides: Investor presentation

Serina Therapeutics doses first patient in SER-252 trial

2026-02-24T21:37:35.000Z - 4 months ago

Serina Therapeutics doses first patient in SER-252 trial

Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Feb 24, 2026, 4:05 PM EST - 4 months ago

Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Serina Therapeutics says first patient enrolled in Phase 1b trial of SER-252

2026-02-19T11:20:45.000Z - 4 months ago

Serina Therapeutics says first patient enrolled in Phase 1b trial of SER-252

Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Feb 19, 2026, 6:00 AM EST - 4 months ago

Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event

Feb 3, 2026, 6:00 AM EST - 5 months ago

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event

Serina Therapeutics files to sell 7.72M shares of common stock for holders

2026-01-30T22:25:13.000Z - 5 months ago

Serina Therapeutics files to sell 7.72M shares of common stock for holders

Serina Therapeutics Registration statement: Registration filing

Jan 30, 2026, 7:00 AM EST - 5 months ago

Serina Therapeutics Registration statement: Registration filing

This Is Why Serina Therapeutics Stock (SER) Rocketed Today

2026-01-29T14:53:03.000Z - 5 months ago

This Is Why Serina Therapeutics Stock (SER) Rocketed Today

Serina Therapeutics announces FDA clearance of SER-252 new drug application

2026-01-28T21:31:30.000Z - 5 months ago

Serina Therapeutics announces FDA clearance of SER-252 new drug application

Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson's disease

Jan 28, 2026, 4:12 PM EST - 5 months ago

Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson's disease

Serina Therapeutics receives NYSE deficiency notice on equity standards

2026-01-15T21:40:23.000Z - 5 months ago

Serina Therapeutics receives NYSE deficiency notice on equity standards

Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity

Jan 15, 2026, 4:30 PM EST - 5 months ago

Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity

Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry

Dec 11, 2025, 4:15 PM EST - 7 months ago

Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry

Serina Therapeutics submits complete response to FDA clinical hold letter

2025-12-10T21:45:32.000Z - 7 months ago

Serina Therapeutics submits complete response to FDA clinical hold letter

Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program

Dec 10, 2025, 4:30 PM EST - 7 months ago

Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program

Serina Therapeutics Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 8 months ago

Serina Therapeutics Quarterly report: Q3 2025

Serina Therapeutics Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 8 months ago

Serina Therapeutics Earnings release: Q3 2025

Serina Therapeutics reports Q3 EPS (45c) vs. 13c last year

2025-11-13T11:15:52.000Z - 8 months ago

Serina Therapeutics reports Q3 EPS (45c) vs. 13c last year

Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Nov 13, 2025, 6:10 AM EST - 8 months ago

Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Serina Therapeutics says FDA places clinical hold on IND for SER-252

2025-11-03T11:16:17.000Z - 8 months ago

Serina Therapeutics says FDA places clinical hold on IND for SER-252

Serina Therapeutics Provides Regulatory Update on SER-252 Program

Nov 3, 2025, 6:05 AM EST - 8 months ago

Serina Therapeutics Provides Regulatory Update on SER-252 Program

Serina Therapeutics Proxy statement: Proxy filing

Oct 27, 2025, 8:00 AM EDT - 8 months ago

Serina Therapeutics Proxy statement: Proxy filing

Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors

Oct 8, 2025, 11:00 AM EDT - 9 months ago

Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors

Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease

Oct 6, 2025, 4:15 PM EDT - 9 months ago

Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease

Serina Therapeutics Proxy statement: Proxy filing

Sep 26, 2025, 8:00 AM EDT - 9 months ago

Serina Therapeutics Proxy statement: Proxy filing

Serina Therapeutics Proxy statement: Proxy filing

Sep 26, 2025, 8:00 AM EDT - 9 months ago

Serina Therapeutics Proxy statement: Proxy filing

Serina Therapeutics Proxy statement: Proxy filing

Sep 15, 2025, 8:00 AM EDT - 10 months ago

Serina Therapeutics Proxy statement: Proxy filing

Serina Therapeutics Inc trading resumes

2025-09-09T20:00:41.000Z - 10 months ago

Serina Therapeutics Inc trading resumes

Serina Therapeutics announces agreement to access up to $20M in financing

2025-09-09T19:30:14.000Z - 10 months ago

Serina Therapeutics announces agreement to access up to $20M in financing

Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease

Sep 9, 2025, 3:20 PM EDT - 10 months ago

Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease

Serina Therapeutics Inc trading halted, news pending

2025-09-09T19:15:24.000Z - 10 months ago

Serina Therapeutics Inc trading halted, news pending

Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 6:00 AM EDT - 10 months ago

Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Serina Therapeutics Stock (SER) Soars 20% on FDA Support

2025-08-27T01:27:00.000Z - 10 months ago

Serina Therapeutics Stock (SER) Soars 20% on FDA Support

Serina Therapeutics Inc trading resumes

2025-08-26T13:45:11.000Z - 10 months ago

Serina Therapeutics Inc trading resumes

Serina Therapeutics Inc trading halted, volatility trading pause

2025-08-26T13:40:26.000Z - 10 months ago

Serina Therapeutics Inc trading halted, volatility trading pause

Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA Pathway

Aug 25, 2025, 4:15 PM EDT - 10 months ago

Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA Pathway

Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Aug 11, 2025, 4:30 PM EDT - 11 months ago

Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Serina Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Serina Therapeutics Earnings release: Q2 2025

Serina Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Serina Therapeutics Quarterly report: Q2 2025

Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)

Jul 29, 2025, 6:44 AM EDT - 11 months ago

Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)

Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference

Jul 28, 2025, 6:00 AM EDT - 1 year ago

Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference

Serina Therapeutics Makes Grant to New Employee Under Inducement Plan

Jul 10, 2025, 4:10 PM EDT - 1 year ago

Serina Therapeutics Makes Grant to New Employee Under Inducement Plan

Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting

Jul 1, 2025, 4:15 PM EDT - 1 year ago

Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

Jun 23, 2025, 7:24 PM EDT - 1 year ago

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42

Jun 17, 2025, 8:30 PM EDT - 1 year ago

UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42

Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42

Jun 17, 2025, 6:00 AM EDT - 1 year ago

Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"

Jun 9, 2025, 4:05 PM EDT - 1 year ago

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"

Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

May 22, 2025, 4:50 PM EDT - 1 year ago

Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

May 14, 2025, 3:15 PM EDT - 1 year ago

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 8, 2025, 4:23 PM EDT - 1 year ago

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

Serina Therapeutics Earnings release: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Serina Therapeutics Earnings release: Q1 2025

Serina Therapeutics Quarterly report: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Serina Therapeutics Quarterly report: Q1 2025

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

Apr 29, 2025, 6:00 AM EDT - 1 year ago

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

Serina Therapeutics Registration statement: Registration filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Serina Therapeutics Registration statement: Registration filing

Serina Therapeutics Slides: Investor presentation

Apr 15, 2025, 7:00 AM EDT - 1 year ago

Serina Therapeutics Slides: Investor presentation

Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit

Apr 15, 2025, 6:30 AM EDT - 1 year ago

Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease

Apr 8, 2025, 4:30 PM EDT - 1 year ago

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease

Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

Apr 7, 2025, 6:30 AM EDT - 1 year ago

Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

Serina Therapeutics Registration statement: Registration filing

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Serina Therapeutics Registration statement: Registration filing

Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Mar 24, 2025, 4:30 PM EDT - 1 year ago

Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Serina Therapeutics Annual report: Q4 2024

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Serina Therapeutics Annual report: Q4 2024

Serina Therapeutics Earnings release: Q4 2024

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Serina Therapeutics Earnings release: Q4 2024

Serina Therapeutics Slides: Investor presentation

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Serina Therapeutics Slides: Investor presentation

Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting

Mar 24, 2025, 6:30 AM EDT - 1 year ago

Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting

Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

Feb 12, 2025, 4:15 PM EST - 1 year ago

Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Feb 3, 2025, 4:30 PM EST - 1 year ago

Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Serina Therapeutics Announces Sale of UniverXome Subsidiary

Jan 15, 2025, 4:05 PM EST - 1 year ago

Serina Therapeutics Announces Sale of UniverXome Subsidiary

Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

Jan 14, 2025, 5:25 PM EST - 1 year ago

Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

Serina Therapeutics Slides: Investor presentation

Jan 6, 2025, 7:00 AM EST - 1 year ago

Serina Therapeutics Slides: Investor presentation

Serina Therapeutics to Present at Tribe Public's Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024

Dec 16, 2024, 6:00 AM EST - 1 year ago

Serina Therapeutics to Present at Tribe Public's Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024

Serina Therapeutics Slides: Investor presentation

Dec 11, 2024, 7:00 AM EST - 1 year ago

Serina Therapeutics Slides: Investor presentation

Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit

Dec 11, 2024, 6:05 AM EST - 1 year ago

Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit

Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Dec 2, 2024, 5:22 PM EST - 1 year ago

Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Nov 12, 2024, 5:00 PM EST - 1 year ago

Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Serina Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Serina Therapeutics Earnings release: Q3 2024

Serina Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Serina Therapeutics Quarterly report: Q3 2024

Serina Therapeutics Proxy statement: Proxy filing

Nov 6, 2024, 7:00 AM EST - 1 year ago

Serina Therapeutics Proxy statement: Proxy filing

Serina Therapeutics Proxy statement: Proxy filing

Nov 6, 2024, 7:00 AM EST - 1 year ago

Serina Therapeutics Proxy statement: Proxy filing

Serina Therapeutics Proxy statement: Proxy filing

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Serina Therapeutics Proxy statement: Proxy filing

Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 6:42 PM EDT - 1 year ago

Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Serina Therapeutics Slides: Corporate presentation

Aug 12, 2024, 7:00 AM EDT - 2 years ago

Serina Therapeutics Slides: Corporate presentation

Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Aug 9, 2024, 4:15 PM EDT - 2 years ago

Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Serina Therapeutics Quarterly report: Q2 2024

Aug 9, 2024, 7:00 AM EDT - 2 years ago

Serina Therapeutics Quarterly report: Q2 2024

Serina Therapeutics Earnings release: Q2 2024

Aug 9, 2024, 7:00 AM EDT - 2 years ago

Serina Therapeutics Earnings release: Q2 2024

Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit

Jul 29, 2024, 8:30 AM EDT - 2 years ago

Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit

Serina Therapeutics Slides: Investor presentation

Jul 29, 2024, 7:00 AM EDT - 2 years ago

Serina Therapeutics Slides: Investor presentation

Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation

Jul 18, 2024, 5:00 PM EDT - 2 years ago

Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation

Serina Therapeutics Registration statement: Registration filing

Jul 3, 2024, 8:00 AM EDT - 2 years ago

Serina Therapeutics Registration statement: Registration filing

Serina Therapeutics Registration statement: Registration filing

Jun 17, 2024, 8:00 AM EDT - 2 years ago

Serina Therapeutics Registration statement: Registration filing

Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

May 14, 2024, 4:05 PM EDT - 2 years ago

Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

littleimagination
littleimagination Jun. 26 at 4:33 PM
$SER Dont you mean 12.5 million? and not 125 mil, I didnt see anything on google or anywhere else stating 125 mil.
0 · Reply
focafoca99
focafoca99 Jun. 24 at 8:23 PM
$SER increased its authorized common shares to 125 million after shareholder approval at its annual meeting.
0 · Reply
Street_secrets
Street_secrets Jun. 24 at 10:33 AM
$SER Small entry... upside on the table
0 · Reply
KaShing01
KaShing01 Jun. 19 at 7:57 PM
$SER I have a hunch Fed Kevin Warsh will surprise everyone and cut rates soon, regardless.
0 · Reply
dthekang
dthekang Jun. 19 at 12:42 AM
$SER something happening?
1 · Reply
Rampageusa
Rampageusa Jun. 18 at 5:51 PM
$SER 7% move….lets go..
0 · Reply
KaShing01
KaShing01 Jun. 17 at 5:18 PM
$SER Just increase my position.
0 · Reply
dthekang
dthekang Jun. 16 at 2:45 PM
$SER 🔥
1 · Reply
dthekang
dthekang Jun. 15 at 3:21 PM
$SER huh?
0 · Reply
robiein35
robiein35 Jun. 11 at 8:06 PM
$SER why the hike? Any news?
1 · Reply
robiein35
robiein35 Jun. 1 at 11:40 PM
$SER Accumulate and hold for 6 months for + or - 100%. Serina expects to advance to the next cohort following a blinded safety review in the third quarter of 2026, with topline data from the study anticipated in the first half of 2027.
1 · Reply
gamgee11
gamgee11 May. 24 at 5:52 PM
$SER
0 · Reply
dthekang
dthekang May. 22 at 3:12 PM
$SER anyone?
0 · Reply
dthekang
dthekang May. 20 at 9:51 AM
$SER anybody here?
0 · Reply
dthekang
dthekang May. 14 at 2:05 PM
$SER cmon…
0 · Reply
SuperGreenToday
SuperGreenToday May. 12 at 12:44 PM
$SER
0 · Reply
MauriceMauriceMaurice
MauriceMauriceMaurice May. 11 at 10:24 PM
$SMMT $EGG $SER
0 · Reply
Monogg
Monogg May. 5 at 10:35 PM
$SER These are scammers—they’ve approved another dilution up to 2 million shares, with the first step being 125,000. Be careful! Do not buy shares of these fraudsters.
0 · Reply
dthekang
dthekang May. 4 at 6:53 PM
$SER
0 · Reply
gmc109
gmc109 Apr. 27 at 4:15 PM
$SER in few days to 4$?
0 · Reply
KaShing01
KaShing01 Apr. 27 at 2:35 PM
$SER
0 · Reply